Latest Conference Articles

December 8th 2020, 3:00pm

ASH Annual Meeting and Exposition

Asciminib demonstrated a statistically significant and clinically meaningful improvement in the major molecular response rate at 24 weeks compared with bosutinib in patients with chronic myeloid leukemia in chronic phase who have received at least 2 prior TKIs.

December 8th 2020, 2:50pm

ASH Annual Meeting and Exposition

December 8, 2020 - Fixed-duration treatment with mosunetuzumab elicited high, durable, and consistent responses across numerous subgroups of patients with follicular lymphoma.

December 8th 2020, 1:54pm

ASH Annual Meeting and Exposition

December 8, 2020 - The combination of umbralisib plus ublituximab plus venetoclax demonstrated encouraging efficacy as treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including those who are refractory to prior therapy with a Bruton tyrosine kinase inhibitor.

December 8th 2020, 1:02pm

ASH Annual Meeting and Exposition

Patients with chronic lymphocytic leukemia who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation.

December 8th 2020, 3:00am

ASH Annual Meeting and Exposition

LOXO-305, an investigational, highly selective, non-covalent BTK inhibitor, demonstrated an investigator-assessed 63% objective response rate in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

December 8th 2020, 1:25am

ASH Annual Meeting and Exposition

December 7, 2020 - Ponatinib resulted in high response rates and robust survival outcomes in patients with chronic-phase chronic myeloid leukemia who have progressed on previous treatment with a second-generation TKI.

December 8th 2020, 12:50am

ASH Annual Meeting and Exposition

December 7, 2020 - In high-risk patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, lisocabtagene maraleucel treatment resulted in a high rate of undetectable minimal residual disease with rapid and durable responses

December 7th 2020, 11:15pm

ASH Annual Meeting and Exposition

Christian Buske, MD, discusses ​the results of the iNNOVATE trial in Waldenström macroglobulinemia.

December 7th 2020, 11:15pm

ASH Annual Meeting and Exposition

December 7, 2020 - The addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone led to improved hematologic complete response rate compared with VCd alone in patients with newly diagnosed amyloid light-chain amyloidosis.

December 7th 2020, 10:31pm

ASH Annual Meeting and Exposition

Panobinostat, given at a 20-mg 3-times-weekly or twice-weekly dosing schedule, in combination with subcutaneous bortezomib and dexamethasone showed durable responses and an acceptable safety profile in patients with relapsed or relapsed/refractory myeloma.

December 7th 2020, 9:55pm

ASH Annual Meeting and Exposition

December 7, 2020 — Findings from the MEDALIST trial demonstrated encouraging clinical efficacy, as well as a tolerable safety profile, with luspatercept among patients with myelodysplastic syndrome and myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.

December 7th 2020, 9:04pm

ASH Annual Meeting and Exposition

December 7, 2020 - Survival rates of adult patients with acute lymphoblastic leukemia who experience relapse following hematopoietic cell transplantation has considerably improved within the past few years, possibly due to the increased use of immunotherapy agents.

December 7th 2020, 8:33pm

ASH Annual Meeting and Exposition

December 7, 2020 - The addition of ixazomib to lenalidomide and dexamethasone resulted in a clinically meaningful 13.5-month improvement in the median progression-free survival of elderly patients with transplant-ineligible newly diagnosed multiple myeloma, although it did not reach statistical significance.

December 7th 2020, 7:40pm

ASH Annual Meeting and Exposition

Daratumumab plus lenalidomide, bortezomib, and dexamethasone followed by daratumumab and lenalidomide maintenance showed a statistically significant improvement in response rates and depth of responses when compared to RVd followed by lenalidomide maintenance for patients with transplant-eligible newly diagnosed multiple myeloma.

December 7th 2020, 7:29pm

ASH Annual Meeting and Exposition

December 7, 2020 — The combination of ublituximab and umbralisib, 2 novel compounds targeting CD20 and PI3Kδ, respectively, has shown synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.

December 7th 2020, 4:16pm

ASH Annual Meeting and Exposition

What started out as a journey to better understand regulatory T cells has now led to an intriguing approach with an investigational cell therapy designed to prevent the risk of graft-versus-host disease and to improve relapse-free survival rates in patients undergoing hematopoietic stem cell transplantation.

December 7th 2020, 4:01pm

ASH Annual Meeting and Exposition

December 7, 2020 — The T-cell–engaging bispecific antibody glofitamab elicited a high rate of complete responses, when given in a step-up dosing schedule, in patients with relapsed/refractory non-Hodgkin lymphoma.

December 7th 2020, 3:34pm

ASH Annual Meeting and Exposition

December 7, 2020 - The addition of subcutaneous daratumumab to pomalidomide and dexamethasone significantly reduced the risk of progression or death by 37%, compared with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma who had received ≥1 prior line of therapy.

December 7th 2020, 2:04am

ASH Annual Meeting and Exposition

December 6, 2020 - Self-reported black race was found to be the most important factor associated with poor survival in patients under 60 years old with acute myeloid leukemia.

December 6th 2020, 11:57pm

ASH Annual Meeting and Exposition

Treatment with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel was found to yield clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.